US › Healthcare

Mink Therapeutics Inc (INKT)

US · Healthcare · Biotechnology

$11.71+1.04%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.1M

EPS

$-0.62

EPS estimate

$-0.60

EPS came in at -0.62 against a street estimate of -0.60 — a miss of 3.3%.

Key statistics

Market cap

$59.1M

Forward P/E

0.0

P/B

11.33

Book value

$-2.75

EPS (TTM)

$-2.35

52-week high

$16.98

52-week low

$8.48

50-day MA

$11.19

200-day MA

$11.39

Beta

0.49

Analyst view

Analysts rate Mink Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $39.00.

Shareholding

Insiders

59.37%

Institutions

4.01%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.16%
DnB NOR Asset Management (Asia)	1.08%
Geode Capital Management, LLC	0.34%
Longbow Finance SA	0.33%
Citadel Advisors Llc	0.30%
UBS Group AG	0.30%
Vanguard Fiduciary Trust Co	0.16%
BlackRock Inc	0.12%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mink Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.